Ontruzant, a biosimilar trastuzumab referencing Herceptin, shows comparable overall survival and cardiac safety, Samsung Bioepis says.
Samsung Bioepis released 3-year follow-up findings of Ontruzant, a biosimilar trastuzumab referencing Herceptin, in early or locally advanced HER2-positive breast cancer, and says it showed comparable overall survival and cardiac safety.
The FDA approved Ontruzant in January for marketing in the United States.
Participants enrolled in an initial phase 3 study received 8 cycles of the biosimilar trastuzumab or the reference medicine concurrently with chemotherapy in the neoadjuvant setting. After surgery, they received additional 10 cycles of the biosimilar trastuzumab or the reference medicine.
After completion of therapy, 367 of these participants (186 in the biosimilar trastuzumab group and 181 in the reference medicine group) were enrolled in the follow-up study. Median follow-up from initiation of study treatment was 40.8 months in the biosimilar trastuzumab group and 40.5 months in the reference medicine group.
Overall survival was 97% in the biosimilar trastuzumab group and 93.6% in the reference medicine group (hazard ratio [HR], 0.39; 95% CI, 0.14-1.12). Event-free survival was 92.5% in the biosimilar trastuzumab group and 86.3% in the reference medicine group (HR, 0.49; 95% CI, 0.26-0.91).
Cardiac events were rare for both treatment groups. There were 3 cases of asymptomatic significant left ventricular ejection fraction (LVEF) decrease (biosimilar trastuzumab, n = 1; reference medicine, n = 2), with all patients recovering with LVEF of 50% or greater. There were no cases of symptomatic congestive heart failure, cardiac death, or other significant cardiac conditions reported in either group.
“With the development of our biosimilar trastuzumab, we aimed to make one of the mainstays of modern cancer therapy more accessible for more people more quickly, and these long-term data underline the importance of that aim,” says Chul Kim, senior vice president and head of clinical sciences division, Samsung Bioepis, in a statement. “We are committed to increasing access to high-quality, life-changing oncology medicines through the development of biosimilars to address some of oncology’s most pressing challenges.”
The drug was first approved by the European Medicines Agency in November 2017, making it the first biosimilar trastuzumab to be approved in the European Union.
The data were presented at the 16th St. Gallen International Breast Cancer Conference 2019 in Austria.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.